Shots:

• The P-III study assesses the safety, reactogenicity & immunogenicity of mRNA-1083 (combination of mRNA-1010 influenza & mRNA-1283 next-gen. COVID-19 vaccine) vs Fluzone HD influenza vaccine & Spikevax COVID-19 vaccine (≥65yrs. age group) as well as Fluarix influenza vaccine & Spikevax (50 to 64yrs. age group); each arm has ~4000 patients
• The vaccine showed overall GMRs for influenza strains of 1.155 (A/H1N1), 1.063 (A/H3N2) & 1.118 (B/Victoria) as well as 1.641 for Omicron XBB.1.5 variant among ≥65yrs. age group
• Furthermore, the GMRs for influenza strains of 1.414 (A/H1N1), 1.380 (A/H3N2) & 1.216 (B/Victoria) as well as 1.308 for Omicron XBB.1.5 variant were observed in 50 to 64yrs. age group. Results will be highlighted at future conferences

Ref: Moderna | Image: Moderna

Related News:- Moderna Collaborates with OpenAI to Advance mRNA Medicine

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com